These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 38022415)

  • 1. Coronary Flow Reserve Changes after Angiotensin Receptor-Neprilysin Inhibitor Treatment in Heart Failure with Reduced Ejection Fraction.
    Karaayvaz EB; Güz G
    Acta Cardiol Sin; 2023 Nov; 39(6):871-878. PubMed ID: 38022415
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Sacubitril/Valsartan vs Standard Medical Therapies on Plasma NT-proBNP Concentration and Submaximal Exercise Capacity in Patients With Heart Failure and Preserved Ejection Fraction: The PARALLAX Randomized Clinical Trial.
    Pieske B; Wachter R; Shah SJ; Baldridge A; Szeczoedy P; Ibram G; Shi V; Zhao Z; Cowie MR;
    JAMA; 2021 Nov; 326(19):1919-1929. PubMed ID: 34783839
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Sacubitril/Valsartan vs Valsartan on Left Atrial Volume in Patients With Pre-Heart Failure With Preserved Ejection Fraction: The PARABLE Randomized Clinical Trial.
    Ledwidge M; Dodd JD; Ryan F; Sweeney C; McDonald K; Fox R; Shorten E; Zhou S; Watson C; Gallagher J; McVeigh N; Murphy DJ; McDonald K
    JAMA Cardiol; 2023 Apr; 8(4):366-375. PubMed ID: 36884247
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sacubitril/Valsartan Improves Left Ventricular Ejection Fraction and Reverses Cardiac Remodeling in Taiwanese Patients with Heart Failure and Reduced Ejection Fraction.
    Liu LW; Wu PC; Chiu MY; Tu PF; Fang CC
    Acta Cardiol Sin; 2020 Mar; 36(2):125-132. PubMed ID: 32201463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of angiotensin receptor neprilysin inhibition on pulmonary arterial stiffness in heart failure with reduced ejection fraction.
    Yenerçağ M; Arslan U; Dereli S; Çoksevim M; Doğduş M; Kaya A
    Int J Cardiovasc Imaging; 2021 Jan; 37(1):165-173. PubMed ID: 32815051
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effect of sacubitril/valsartan on cardiac function in heart failure rabbits with preserved ejection fraction].
    Gao SY; Yao DH; Li JF; Xie QM; Jiang SC
    Zhonghua Xin Xue Guan Bing Za Zhi; 2019 Nov; 47(11):887-893. PubMed ID: 31744278
    [No Abstract]   [Full Text] [Related]  

  • 7. Effects of sacubitril/valsartan in ESRD patients undergoing hemodialysis with HFpEF.
    Guo Y; Ren M; Wang T; Wang Y; Pu T; Li X; Yu L; Wang L; Liu P; Tang L
    Front Cardiovasc Med; 2022; 9():955780. PubMed ID: 36440034
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Longitudinal Changes in Natriuretic Peptides and Reverse Cardiac Remodeling in Patients with Heart Failure Treated with Sacubitril/Valsartan Across the Left Ventricular Ejection Traction Spectrum.
    Yamamoto M; Ishizu T; Sato K; Minami K; Terauchi T; Nakatsukasa T; Kawamatsu N; Machino-Ohtsuka T; Ieda M
    Int Heart J; 2023 Nov; 64(6):1071-1078. PubMed ID: 37967975
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of sacubitril/valsartan on neprilysin targets and the metabolism of natriuretic peptides in chronic heart failure: a mechanistic clinical study.
    Nougué H; Pezel T; Picard F; Sadoune M; Arrigo M; Beauvais F; Launay JM; Cohen-Solal A; Vodovar N; Logeart D
    Eur J Heart Fail; 2019 May; 21(5):598-605. PubMed ID: 30520545
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of Sacubitril/Valsartan Compared With Ramipril on Cardiac Structure and Function After Acute Myocardial Infarction: The PARADISE-MI Echocardiographic Substudy.
    Shah AM; Claggett B; Prasad N; Li G; Volquez M; Jering K; Cikes M; Kovacs A; Mullens W; Nicolau JC; Køber L; van der Meer P; Jhund PS; Ibram G; Lefkowitz M; Zhou Y; Solomon SD; Pfeffer MA
    Circulation; 2022 Oct; 146(14):1067-1081. PubMed ID: 36082663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of sacubitril/valsartan on echo parameters in heart failure patients with reduced ejection fraction a prospective evaluation.
    Bayard G; Da Costa A; Pierrard R; Roméyer-Bouchard C; Guichard JB; Isaaz K
    Int J Cardiol Heart Vasc; 2019 Dec; 25():100418. PubMed ID: 31517034
    [TBL] [Abstract][Full Text] [Related]  

  • 12. B-Type Natriuretic Peptide During Treatment With Sacubitril/Valsartan: The PARADIGM-HF Trial.
    Myhre PL; Vaduganathan M; Claggett B; Packer M; Desai AS; Rouleau JL; Zile MR; Swedberg K; Lefkowitz M; Shi V; McMurray JJV; Solomon SD
    J Am Coll Cardiol; 2019 Mar; 73(11):1264-1272. PubMed ID: 30846338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of Change in N-Terminal Pro-B-Type Natriuretic Peptide Following Initiation of Sacubitril-Valsartan Treatment With Cardiac Structure and Function in Patients With Heart Failure With Reduced Ejection Fraction.
    Januzzi JL; Prescott MF; Butler J; Felker GM; Maisel AS; McCague K; Camacho A; Piña IL; Rocha RA; Shah AM; Williamson KM; Solomon SD;
    JAMA; 2019 Sep; 322(11):1085-1095. PubMed ID: 31475295
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NT-proBNP Response to Sacubitril/Valsartan in Hospitalized Heart Failure Patients With Reduced Ejection Fraction: TRANSITION Study.
    Pascual-Figal D; Wachter R; Senni M; Bao W; Noè A; Schwende H; Butylin D; Prescott MF;
    JACC Heart Fail; 2020 Oct; 8(10):822-833. PubMed ID: 32800508
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Initial clinical experience with the first drug (sacubitril/valsartan) in a new class - angiotensin receptor neprilysin inhibitors in patients with heart failure with reduced left ventricular ejection fraction in Poland.
    Kałużna-Oleksy M; Kolasa J; Migaj J; Pawlak A; Lelonek M; Nessler J; Straburzyńska-Migaj E
    Kardiol Pol; 2018; 76(2):381-387. PubMed ID: 29192956
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of Sacubitril/Valsartan on cardiac function and cardiac remodeling in patients with heart failure with reduced ejection fraction.
    Chen F; Tian G; Bai X; Li J; Yuan Z
    Ann Palliat Med; 2021 Aug; 10(8):8684-8691. PubMed ID: 34488357
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional changes in the heart after sacubitril/valsartan use in 5 hemodialysis patients with hypertension. Case report.
    Kuwae N
    CEN Case Rep; 2023 Nov; ():. PubMed ID: 37995053
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rationale and design of the comParIson Of sacubitril/valsartaN versus Enalapril on Effect on nt-pRo-bnp in patients stabilized from an acute Heart Failure episode (PIONEER-HF) trial.
    Velazquez EJ; Morrow DA; DeVore AD; Ambrosy AP; Duffy CI; McCague K; Hernandez AF; Rocha RA; Braunwald E
    Am Heart J; 2018 Apr; 198():145-151. PubMed ID: 29653636
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world treatment switching to sacubitril/valsartan in patients with heart failure with reduced ejection fraction: A cohort study.
    Ganesananthan S; Shah N; Shah P; Elsayed H; Phillips J; Parkes A; Morgan A; Yousef Z
    Open Heart; 2020 Oct; 7(2):. PubMed ID: 33020255
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insights into implementation of sacubitril/valsartan into clinical practice.
    Martens P; Beliën H; Dupont M; Mullens W
    ESC Heart Fail; 2018 Jun; 5(3):275-283. PubMed ID: 29464879
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.